HPR51 Should Volume-Based Procurement Price of Comparator be Referenced for Innovative Drugs in National Reimbursement Drug List Negotiation in China?
Abstract
Authors
J. Wu J. Liu J. Ming S. Qu T. Wei L. Zhu J. Chen
J. Wu J. Liu J. Ming S. Qu T. Wei L. Zhu J. Chen
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now